Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit

J. King, D.H. Palmer, P. Johnson, P. Ross, R.A. Hubner, K. Sumpter, S. Darby, C. Braconi, C. Iwuji, D. Swinson, P. Collins, K. Patel, J. Nobes, I. Muazzam, C. Blesing, A. Kirkwood, S. Nash, T. Meyer

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Aims Sorafenib is the current standard treatment for advanced hepatocellular carcinoma. We carried out a national audit of UK patients treated with sorafenib as standard-of-care and those treated with systemic therapy in first-line trials. Materials and methods Sorafenib-treated and trial-treated patients were identified via the Cancer Drugs Fund and local databases. Data were collected retrospectively from medical records according to a standard case report form. The primary outcome measure was overall survival, estimated by the Kaplan–Meier method. Results Data were obtained for 448 sorafenib-treated patients from 15 hospitals. The median age was 68 years (range 17–89) and 75% had performance status ≤ 1. At baseline, 77% were Child-Pugh A and 16.1% Child-Pugh B; 38% were albumin–bilirubin grade 1 (ALBI-1) and 48% ALBI-2; 23% were Barcelona Clinic Liver Classification B (BCLC-B) and 72% BCLC-C. The median time on sorafenib was 3.6 months, with a mean daily dose of 590 mg. The median overall survival for 448 evaluable sorafenib-treated patients was 8.5 months. There were significant differences in overall survival comparing Child-Pugh A versus Child-Pugh B (9.5 versus 4.6 months), ALBI-1 versus ALBI-2 (12.9 versus 5.9 months) and BCLC-B versus BCLC-C (13.0 versus 8.3 months). For trial-treated patients (n = 109), the median overall survival was 8.1 months and this was not significantly different from the sorafenib-treated patients. Conclusion For Child-Pugh A patients with good performance status, survival outcomes were similar to those reported in global randomised controlled trials. Patients with ALBI grade > 1, Child-Pugh B or poor performance status seem to derive limited benefit from sorafenib treatment.
Original languageEnglish
Number of pages7
JournalClinical Oncology
Early online date10 Dec 2016
Publication statusE-pub ahead of print - 10 Dec 2016


  • ALBI
  • Child-Pugh
  • hepatocellular carcinoma
  • prognosis
  • sorafenib


Dive into the research topics of 'Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit'. Together they form a unique fingerprint.

Cite this